Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05540457 · ClinicalTrials.gov registry record · NA
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
A NA study, sponsored by The Rogosin Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT05540457 is a NA study that has completed, run by The Rogosin Institute. The registered enrollment target is 10 participants.
The verdict
NCT05540457, a NA study, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Prospective, single center, open label, non-randomized, post-market study of the Tablo Hemodialysis System and VitalStream Monitor in participants with End-Stage KidneyDisease undergoing In-Center Hemodialysis.
Interventions
- DEVICE Intermittent Non-InvasiveBlood Pressure Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2024-02-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05540457
The ClinicalTrials.gov registry entry for NCT05540457 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intermittent Non-InvasiveBlood Pressure Monitor is the first listed.
NCT05540457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05540457 about?
NCT05540457 is a clinical study titled "Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)". Prospective, single center, open label, non-randomized, post-market study of the Tablo Hemodialysis System and VitalStream Monitor in participants with End-Stage KidneyDisease undergoing In-Center Hemodialysis.
What is the current status of trial NCT05540457?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2022-09-22. Estimated completion is 2024-02-09.
What interventions are being tested in trial NCT05540457?
The interventions under investigation include: Intermittent Non-InvasiveBlood Pressure Monitor (DEVICE).
Who is sponsoring clinical trial NCT05540457?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.